Insight Molecular Diagnostics (IMDX) Change in Receivables (2020 - 2026)

Insight Molecular Diagnostics has disclosed Change in Receivables across 7 years of filings, most recently posting -$971000.0 for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$971000.0, down 150.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.4 million (down 200.12% YoY), and the FY2025 annual result was -$485000.0, down 142.96% from the prior year.
• Change in Receivables came in at -$971000.0 for Q1 2026 at Insight Molecular Diagnostics, down from $870000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $1.9 million in Q1 2025 to a low of -$3.0 million in Q2 2025.
• The 5-year median for Change in Receivables is $21000.0 (2023), against an average of $8176.5.
• Across the five-year window, Change in Receivables soared 6585.71% in 2024 and sank 3884.21% in 2025, its largest moves.
• Insight Molecular Diagnostics' Change in Receivables stood at $22000.0 in 2022, then fell by 4.55% to $21000.0 in 2023, then jumped by 6585.71% to $1.4 million in 2024, then plunged by 38.03% to $870000.0 in 2025, then tumbled by 211.61% to -$971000.0 in 2026.
• The last three Change in Receivables figures came in at -$971000.0 (Q1 2026), $870000.0 (Q4 2025), and -$254000.0 (Q3 2025), per Business Quant data.